Agents targeting prostate cancer bone metastasis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Bone is the most common site for metastasis of advanced prostate cancers. Once housed in the skeleton, tumors are incurable and cause protracted morbidity, and bone metastases may contribute to mortality through unknown mechanisms. Bone provides a unique microenvironment whose local interactions with tumor cells offer novel targets for therapeutic interventions. Many standard cancer treatments cause bone loss, which may aggravate skeletal metastases, although this is preventable with approved agents. Improved bone-targeted treatments can decrease the serious skeletal morbidities associated with metastatic prostate cancer and may in the future improve overall survival. The development of such treatments requires preclinical evaluation in animal models of prostate cancer growth in bone.

Original languageEnglish
Pages (from-to)1079-1088
Number of pages10
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume9
Issue number10
DOIs
StatePublished - 2009

Fingerprint

Bone Neoplasms
Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Morbidity
Neoplasms
Bone Development
Skeleton
Animal Models
Mortality

Keywords

  • Bisphosphonate
  • Bone
  • Endothelin
  • Metastasis
  • Osteoblastic
  • Osteolytic
  • Prostate cancer
  • RANK ligand
  • TGF-beta

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Agents targeting prostate cancer bone metastasis. / Mohammad, Khalid; Fournier, Pierrick G.; Guise, Theresa; Chirgwin, John.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 9, No. 10, 2009, p. 1079-1088.

Research output: Contribution to journalArticle

@article{e156b59dd06f45bcb0d17a79d7ba1baa,
title = "Agents targeting prostate cancer bone metastasis",
abstract = "Bone is the most common site for metastasis of advanced prostate cancers. Once housed in the skeleton, tumors are incurable and cause protracted morbidity, and bone metastases may contribute to mortality through unknown mechanisms. Bone provides a unique microenvironment whose local interactions with tumor cells offer novel targets for therapeutic interventions. Many standard cancer treatments cause bone loss, which may aggravate skeletal metastases, although this is preventable with approved agents. Improved bone-targeted treatments can decrease the serious skeletal morbidities associated with metastatic prostate cancer and may in the future improve overall survival. The development of such treatments requires preclinical evaluation in animal models of prostate cancer growth in bone.",
keywords = "Bisphosphonate, Bone, Endothelin, Metastasis, Osteoblastic, Osteolytic, Prostate cancer, RANK ligand, TGF-beta",
author = "Khalid Mohammad and Fournier, {Pierrick G.} and Theresa Guise and John Chirgwin",
year = "2009",
doi = "10.2174/187152009789735008",
language = "English",
volume = "9",
pages = "1079--1088",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Agents targeting prostate cancer bone metastasis

AU - Mohammad, Khalid

AU - Fournier, Pierrick G.

AU - Guise, Theresa

AU - Chirgwin, John

PY - 2009

Y1 - 2009

N2 - Bone is the most common site for metastasis of advanced prostate cancers. Once housed in the skeleton, tumors are incurable and cause protracted morbidity, and bone metastases may contribute to mortality through unknown mechanisms. Bone provides a unique microenvironment whose local interactions with tumor cells offer novel targets for therapeutic interventions. Many standard cancer treatments cause bone loss, which may aggravate skeletal metastases, although this is preventable with approved agents. Improved bone-targeted treatments can decrease the serious skeletal morbidities associated with metastatic prostate cancer and may in the future improve overall survival. The development of such treatments requires preclinical evaluation in animal models of prostate cancer growth in bone.

AB - Bone is the most common site for metastasis of advanced prostate cancers. Once housed in the skeleton, tumors are incurable and cause protracted morbidity, and bone metastases may contribute to mortality through unknown mechanisms. Bone provides a unique microenvironment whose local interactions with tumor cells offer novel targets for therapeutic interventions. Many standard cancer treatments cause bone loss, which may aggravate skeletal metastases, although this is preventable with approved agents. Improved bone-targeted treatments can decrease the serious skeletal morbidities associated with metastatic prostate cancer and may in the future improve overall survival. The development of such treatments requires preclinical evaluation in animal models of prostate cancer growth in bone.

KW - Bisphosphonate

KW - Bone

KW - Endothelin

KW - Metastasis

KW - Osteoblastic

KW - Osteolytic

KW - Prostate cancer

KW - RANK ligand

KW - TGF-beta

UR - http://www.scopus.com/inward/record.url?scp=73349087170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349087170&partnerID=8YFLogxK

U2 - 10.2174/187152009789735008

DO - 10.2174/187152009789735008

M3 - Article

C2 - 19719455

AN - SCOPUS:73349087170

VL - 9

SP - 1079

EP - 1088

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 10

ER -